Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer

An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-01, Vol.160, p.227-234
Hauptverfasser:	Mizugaki, Hidenori, Oizumi, Satoshi, Fujita, Yuka, Harada, Toshiyuki, Nakahara, Yoshiro, Takashina, Taichi, Ko, Ryo, Watanabe, Kageaki, Hotta, Takamasa, Minemura, Hiroyuki, Saeki, Sho, Asahina, Hajime, Nakamura, Keiichi, Nakamura, Hiromi, Hosoda, Fumie, Yagishita, Shigehiro, Hamada, Akinobu
Format:	Artikel
Sprache:	eng
Schlagworte:	Afatinib - pharmacokinetics Afatinib - pharmacology Afatinib - therapeutic use Aged Aging Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Disease control EGFR mutation Elderly patients Epidermal growth factor receptors Female Geriatrics Humans Low-dose afatinib Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Mutation Non-small cell lung carcinoma Older people Patients Pharmacogenomics Pharmacokinetics Pharmacology Population studies Progression-Free Survival Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Quality assessment Small cell lung carcinoma Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!